Form 4: Catalyst Pharma CCO Exercises Options, Sells Stock

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, exercised options and subsequently sold 10,983 shares of common stock for personal reasons.

Summary

• Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions on November 26, 2025.
• Mr. Del Carmen exercised options to purchase 10,983 shares of common stock at an exercise price of $4.21 per share.
• Concurrently, he sold 10,983 shares of common stock on the open market at a weighted average price of $23.331 per share, with individual sales ranging from $23.331 to $23.345.
• Following these transactions, Mr. Del Carmen directly owns 3,962 shares of common stock.
• He also beneficially owns 1,053,552 derivative securities (options to purchase common stock) after the reported transactions.
• The options exercised were part of a grant that previously vested in three annual tranches, beginning on January 6, 2021, and are set to expire on January 6, 2027.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While an insider sale can sometimes be viewed negatively, the explicit statement of 'personal reasons' mitigates concerns about company disagreement. The executive realized a substantial profit, reflecting positively on the stock's performance, and still retains a significant number of options, indicating continued vested interest.

Positives

• The Chief Commercial Officer realized a significant gain by exercising options at $4.21 and selling shares at a weighted average of $23.331, demonstrating the value appreciation of the company's stock.
• The executive retains a substantial number of options (1,053,552), indicating continued alignment with the company's future performance.

Negatives

• An insider sale, even for personal reasons, can sometimes be perceived negatively by the market, potentially raising questions about management's long-term outlook, though the filing explicitly states personal reasons.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Industry Context

This insider transaction report reflects an individual executive's stock activity and does not directly provide insights into broader industry trends or competitive landscape. However, the ability of an executive to realize significant gains from stock options can be seen as a positive indicator of the company's performance within its sector over time.

Stakeholder Impact

• Shareholders may observe the Chief Commercial Officer's sale of shares, which could lead to minor shifts in market sentiment, despite the stated personal reasons for the transaction.
• The transaction demonstrates the potential for executives to realize value from their equity compensation, which can be a positive for employee morale and retention.

Key Dates

Recommendation

The Chief Commercial Officer's sale of shares, while significant in volume, was explicitly stated to be for personal reasons and not indicative of any disagreement with Catalyst Pharmaceuticals. The executive retains a substantial number of unexercised options, maintaining a vested interest in the company's future. This single transaction, therefore, does not fundamentally alter the investment thesis for CPRX, warranting a 'hold' recommendation as investors should consider it as a data point rather than a signal for a change in company fundamentals.

Keywords

Catalyst Pharmaceuticals, CPRX, Insider Trading, Form 4, Stock Sale, Option Exercise, Jeffrey Del Carmen, Chief Commercial Officer, Biotechnology, Pharmaceuticals